Evaluation of the performance of a rapid antigen test (Roche) for COVID-19 diagnosis in an emergency setting in Sweden

Abstract

During the ongoing COVID-19 pandemic, rapid and reliable detection of SARS-CoV-2 is important to enable proper care of patients and to prevent further transmission. The aim of this study was to evaluate the performance of the Roche SARS-CoV-2 Rapid Antigen Test (Ag-RDT) in an emergency care setting during a high pandemic period. The analytical performance of the Ag-RDT was compared to real-time reverse transcriptase polymerase chain reaction (rRT-PCR). A total of 132 patient samples, previously analyzed with rRT-PCR, were reanalyzed with the Ag-RDT. Tenfold serial dilutions of five different patient strains containing the pangolin variants BA.1, BA.2, B.1.1.7, B.1.160, and B.1.177 were analyzed in parallel with the Ag-RDT and rRT-PCR. A clinical evaluation was performed in which 1911 consecutive patients admitted to the emergency wards in Region Gävleborg, Sweden, were included. Paired samples were collected and analyzed with the Ag-RDT on-site and with rRT-PCR at the microbiology laboratory. The overall sensitivity and specificity of the Ag-RDT in the clinical evaluation were 71.3% and 99.7%, respectively. When samples with cycle threshold (Ct) values above 30 were excluded, the sensitivity was 86.5%. Eleven of the admitted patients who were positive for both the Ag-RDT and rRT-PCR (Ct-range 16.9-30.4) showed no symptoms of COVID-19. Using the Ag-RDT shortened the detection time by an average of 11 h. The Ag-RDT is a useful tool for preliminary screening of SARS-CoV-2 because it enables rapid detection in infectious individuals and therefore, can counteract unnecessary spread of infection at an early stage.

Keywords: COVID-19; SARS-CoV-2; rapid antigen test.